EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-july-2023
#SafetyOfMedicines https://t.co/D0EHywwIMF
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1677261762968662016
At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1667127819984306176
At its monthly meeting, EMA's safety committee, the PRAC, started a review of medicines ๐containing #hydroxyprogesterone and issued a reminder on the restrictions in the use of fluoroquinolone #antibiotics.
More information below ๐
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1657022453464330250
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1636691621998673920
At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.
#PublicHealth #SafetyOfMedicines
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1624037832950939650
At its January meeting, our safety committee ๐๐, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1613886224040710148
RT @EMA_News: At its January meeting, our safety committee ๐๐, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
๐ฆ๐: https://n.respublicae.eu/Food_EU/status/1613888043802394627
โ๏ธOur safety committee, the PRAC, recommends the withdrawal of pholcodine #medicines against dry cough from the EU market. Read more in our highlights.
๐https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-november-1-december-2022
#pharmacovigilance #safetyofmedicines
๐ฆ๐: https://n.respublicae.eu/EMA_News/status/1598661917689712642
The #PRAC recommended measures to minimise risk of serious #sideeffects with Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic
๐ฆ๐: https://nitter.eu/EMA_News/status/1585941029844582400
EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.๐
๐ Find all safety reviews under evaluation in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-may-2022
๐ฆ๐: https://nitter.eu/EMA_News/status/1522542450744639489
EU Medicines Agency
EU Food Safety - #EUFarm2Fork